Harbour Investments’s Cellectar Biosciences CLRB Stock Holding History

Harbour Investments’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$7	–	3768
2025 Q2	$7	Sell	1 -1	-50%	-$9	﹤0.01%	3590
2025 Q1	$16	Buy	2 +1	+100%	+$9	﹤0.01%	3527
2024 Q4	$12	Hold	1	–	–	﹤0.01%	3467
2024 Q3	$86	Hold	1	–	–	﹤0.01%	3322
2024 Q2	$100	Hold	1	–	–	﹤0.01%	3205
2024 Q1	$159	Hold	1	–	–	﹤0.01%	3127
2023 Q4	$111	Hold	1	–	–	﹤0.01%	3041
2023 Q3	$106	Hold	1	–	–	﹤0.01%	2922
2023 Q2	$78	Hold	1	–	–	﹤0.01%	2967
2023 Q1	$57	Hold	1	–	–	﹤0.01%	2950
2022 Q4	$68	Buy	+1	New	+$60	﹤0.01%	2944
2021 Q4	$0	Sell	1 -59	-98%	-$14.2K	﹤0.01%	2802
2021 Q3	$17K	Buy	60 +34	+131%	+$10.4K	﹤0.01%	2372
2021 Q2	$9K	Buy	26 +3	+13%	+$1.3K	﹤0.01%	2783
2021 Q1	$11K	Buy	+23	New	+$13.7K	﹤0.01%	2543

Other funds holding CLRB

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SFA

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

RCA

Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbour Investments's CLRB Position: Q3 2025 in Review

Harbour Investments sold out of Cellectar Biosciences (CLRB) in Q3 2025, closing a stake of 1 share — an estimated $7 sold.

Harbour Investments first reported a position in CLRB in Q1 2021 and held it in 15 quarters. The position peaked at $17K in Q3 2021. 21 funds tracked by Wall St. Rank hold CLRB as of Q3 2025.

Harbour Investments reported no remaining Cellectar Biosciences position as of Q3 2025 after selling out during the quarter.
Harbour Investments sold 1 Cellectar Biosciences share in Q3 2025, an estimated $7.
Harbour Investments first reported a position in Cellectar Biosciences in Q1 2021 and held it in 15 quarters.
Harbour Investments's Cellectar Biosciences position peaked at $17K in Q3 2021.
21 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2025.

Based on Harbour Investments's 13F filing for Q3 2025, filed 12 Nov 2025.